Facilities

Cell Genesys secures Memphis facility for lung cancer vaccines

Published in Vaccine Weekly, April 17th, 2002

Cell Genesys, Inc., (CEGE) has leased a 35,000 square-foot facility in Memphis, Tennessee, which it plans to use to manufacture the company's patient-specific GVAX lung cancer vaccines for both phase III clinical trials and potential market launch.

Memphis, one of the major shipping hubs in the world, was chosen to facilitate the efficient transport and distribution of patient vaccines to treatment centers across the United States.

The facility sets the stage for Cell Genesys' product development strategy for GVAX lung cancer vaccines which includes establishing a centrally located GMP (good manufacturing practices) facility to receive and process...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-04-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry